Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this research study is to collect information to learn how effective
erlotinib (tarceva) is in combination with either bevacizumab or sulindac in treating
patients with squamous cell carcinoma of the head and neck. Erlotinib and bevacizumab are
targeted therapy drugs that can control tumor growth by targeting specific abnormalities
sometimes found on cancer cells. Erlotinib targets epidermal growth factor receptor (EGFR),
and bevacizumab targets vascular endothelial growth factor (VEGF). Sulindac is a
non-steroidal anti-inflammatory drug (NSAID) that can block G protein-coupled receptor which
laboratory evidence shows is associated with both cancer cell growth and EGFR activity. The
bevacizumab being administered in this study is not a commercially marketed formulation of
the drug. Previous research with head and neck cancer suggest that erlotinib alone has some
anti-cancer activity. This research study is designed to see how well erlotinib works in
combination with bevacizumab or sulindac in head and neck cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Dana-Farber Cancer Institute Emory University Genentech, Inc. OSI Pharmaceuticals University of North Carolina, Chapel Hill